Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Proteases represent one of the largest enzyme families encoded by the human genome. By catalyzing the hydrolysis of peptide bonds, they regulate a wide array of physiological and pathological processes, including cell proliferation, tissue remodeling, embryonic development, coagulation, blood pressure regulation, protein activation and degradation, inflammatory responses, infection, and tumorigenesis. The human degradome comprises at least 569 proteases, categorized into five major classes: metalloproteases, serine proteases, cysteine proteases, threonine proteases, and aspartic proteases. Due to their central roles in disease mechanisms, proteases have become highly valued drug targets. Successful inhibitors of key proteases, such as HIV protease, matrix metalloproteases (MMPs), dipeptidyl peptidases (DPPs), and angiotensin-converting enzyme (ACE), have demonstrated significant clinical efficacy in treating hypertension, diabetes, HIV infection, and coagulation disorders.
Figure 1. Protease basics. (Turk B. 2006)
To support diverse protease-targeted drug discovery needs, Creative Biogene has established a comprehensive protease screening and functional profiling platform. Covering more than 50 protease targets across metalloproteases, serine proteases, cysteine proteases, aspartic proteases, and threonine proteases, our platform integrates multiple assay technologies and resources to facilitate compound evaluation throughout the drug discovery pipeline.
Table 1. Protease screening targets
| Metalloprotease | MMP1 | MMP2 | MMP3 | MMP7 | MMP8 |
| MMP9 | MMP10 | MMP12 | MMP13 | MMP14 | |
| Neprilisin | TACE | ADAM10 | ACE1 | ACE2 | |
| Serine protease | Kallikrein1 | Kallikrein5 | Kallikrein7 | Kallikrein12 | Kallikrein13 |
| Kallikrein14 | DPP3 | DPP4 | DPP7 | DPP8 | |
| DPP9 | HCV1a | HCV1b | HCV2a | Matriptase2 | |
| Chymase | Proteinase A | Proteinase K | Thrombin | Trypsin b2 | |
| Trypsin g1 | Urokinase | Factor VIIa | Factor Xa | Factor XIa | |
| Elastase | Cathepsin G | Chymotrypsin | |||
| Cysteine protease | Papain | Calpain 1 | Cathepsin B | Cathepsin C | Cathepsin H |
| Cathepsin L | Cathepsin S | Cathepsin V | MALT1 | UCHL1 | |
| USP1 | USP2 | USP3 | Calpain 2 | UCHL3 | |
| Aspartic Protease | HIV-1 | BACE1 | Caspase-1 | Caspase-3 | Caspase-6 |
| Caspase-7 | Caspase-8 | Caspase-9 | Caspase-4 | ||
| Threonine protease | PSMA1 | PSMA2 | PSMA3 | PSMA4 | PSMA5 |
| PSMA6 | PSMA7 | GGT1 | GGT2 |
Our platform has supported drug discovery projects across antiviral agents (HCV and HIV protease inhibitors), antithrombotics (thrombin and factor Xa inhibitors), metabolic disease therapies (DPP-4 inhibitors), and anticancer drugs (proteasome and cathepsin inhibitors). We offer tailored solutions grounded in a deep understanding of protease biology and family-specific challenges.
Creative Biogene maintains rigorous quality control and a highly experienced research team to ensure reliable, reproducible experimental data. Every step—from protein expression and purification to activity verification, assay optimization, and data analysis—is carefully monitored. Flexible service models accommodate unique project requirements, from basic functional validation to complex mechanistic studies, providing professional technical support throughout.
For more information about our protease service platform or to discuss a specific research project, please contact us. We are committed to supporting your innovative drug discovery initiatives with professional expertise and comprehensive analytical insights.